These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 8201244)

  • 21. [Serotonin (5-HT)3 receptors: antagonists and their pharmacological profiles].
    Miyata K; Honda K
    Nihon Yakurigaku Zasshi; 1994 Sep; 104(3):143-52. PubMed ID: 7959407
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Animal models for anxiety and response to serotonergic drugs.
    Broekkamp CL; Berendsen HH; Jenck F; Van Delft AM
    Psychopathology; 1989; 22 Suppl 1():2-12. PubMed ID: 2567038
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serotonin receptors: subtypes, functional responses and therapeutic relevance.
    Saxena PR
    Pharmacol Ther; 1995 May; 66(2):339-68. PubMed ID: 7667401
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Thymosthenic agents, a novel approach in the treatment of schizophrenia.
    Gelders YG
    Br J Psychiatry Suppl; 1989 Jul; (5):33-6. PubMed ID: 2481482
    [No Abstract]   [Full Text] [Related]  

  • 25. Ethanol- and diazepam-withdrawal hyperlocomotion is not due to 5-HT3 receptor stimulation.
    Mehta AK; Ticku MK
    Pharmacol Biochem Behav; 1993 Jul; 45(3):755-7. PubMed ID: 8332636
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapeutic potential of drugs with mixed 5-HT4 agonist/5-HT3 antagonist action in the control of emesis.
    Tonini M; Candura SM; Messori E; Rizzi CA
    Pharmacol Res; 1995 May; 31(5):257-60. PubMed ID: 7479521
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Opportunities for treatment of psychoactive substance use disorders with serotonergic medications.
    Sellers EM; Higgins GA; Tomkins DM; Romach MK; Toneatto T
    J Clin Psychiatry; 1991 Dec; 52 Suppl():49-54. PubMed ID: 1752860
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effects of 5-HT3 receptor antagonists in models of dependency and withdrawal.
    Costall B; Domeney AM; Kelly ME; Naylor RJ
    Alcohol Alcohol Suppl; 1993; 2():269-73. PubMed ID: 7748309
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Zatosetron. LY 191617, LY 277359.
    Drugs R D; 1999 Oct; 2(4):253-5. PubMed ID: 10659404
    [No Abstract]   [Full Text] [Related]  

  • 30. [Central serotonin receptors. Principal fundamental and functional aspects. Therapeutic applications].
    Moulignier A
    Rev Neurol (Paris); 1994; 150(1):3-15. PubMed ID: 7801037
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The psychopharmacology of 5-HT3 receptors.
    Costall B; Naylor RJ; Tyers MB
    Pharmacol Ther; 1990; 47(2):181-202. PubMed ID: 2203069
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interactions between 5-HT3 receptors and cerebral dopamine function: implications for the treatment of schizophrenia and psychoactive substance abuse.
    Hagan RM; Kilpatrick GJ; Tyers MB
    Psychopharmacology (Berl); 1993; 112(1 Suppl):S68-75. PubMed ID: 7831443
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serotonin receptor subtypes and neuropsychiatric diseases: focus on 5-HT1D and 5-HT3 receptor agents.
    Peroutka SJ
    Pharmacol Rev; 1991 Dec; 43(4):579-86. PubMed ID: 1663621
    [No Abstract]   [Full Text] [Related]  

  • 34. The role of 5-HT3 receptors in drug dependence.
    Grant KA
    Drug Alcohol Depend; 1995 May; 38(2):155-71. PubMed ID: 7671767
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 5-HT2A antagonists in psychiatric disorders.
    de Angelis L
    Curr Opin Investig Drugs; 2002 Jan; 3(1):106-12. PubMed ID: 12054060
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Is there a relationship between serotonin receptor subtypes and selectivity of response in specific psychiatric illnesses?
    Montgomery SA; Fineberg N
    Br J Psychiatry Suppl; 1989 Dec; (8):63-9. PubMed ID: 2692641
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy.
    Gregory RE; Ettinger DS
    Drugs; 1998 Feb; 55(2):173-89. PubMed ID: 9506240
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of various 5-HT3 receptor antagonists, granisetron, ondansetron, ramosetron and azasetron on serotonin (5-HT) release from the ferret isolated ileum.
    Endo T; Minami M; Kitamura N; Teramoto Y; Ogawa T; Nemoto M; Hamaue N; Hirafuji M; Yasuda E; Blower PR
    Res Commun Mol Pathol Pharmacol; 1999; 104(2):145-55. PubMed ID: 10634307
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Studies on the effects of certain 5-HT-3 receptor antagonists on ethanol preference and withdrawal seizures in the rat.
    Kostowski W; Bisaga A; Jankowska E; Krzaścik P
    Pol J Pharmacol; 1994; 46(3):133-7. PubMed ID: 8000444
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 5-HT3 receptors and the therapeutic potential of 5-HT3 receptor antagonists.
    Tyers MB
    Therapie; 1991; 46(6):431-5. PubMed ID: 1840227
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.